Tenofovir in HBV treatment

On the third day of APASL, Professor Patrick Marcellin made a presentation entitled  Now will Tenofovir Change the Choice of Anti-viral Agents. In this study, patients with HBeAg-positive (+) or HBeAg-negative (-) CHB were randomized to double-blind, tenofovir disoproxil fumarate (TDF) or adefovir dipivoxil (ADV). After 48 weeks, patients rolled to open-label (OL) TDF for an additional 7 years. The results up to week 96 were as follows: HBeAg+: At W96, viral suppression on ADV was maintained/enhanced after rolling to TDF (ADV-TDF): 100% of stable and 82% viremic patients on ADV had HBV DNA <400 copies (c)/ml at W96. In an intent-to-treat (ITT) analysis, 78% of ADV-TDF patients had HBV DNA <400 c/ml at W96, as the same as the percentage in TDF-TDF patients. 27% (TDF-TDF) and 22% (ADV-TDF) HBeAg seroconverted (P=0.31). 6% in both groups experienced HBsAg loss. One patient discontinued due to an adverse event. Moreover, the groups of HBeAg negative had the similar conclusions.

Professor  Marcellin concluded that TDF produced potent, continuous viral suppression and was well tolerated through 96 weeks. Patients rolling to TDF after 48 weeks of ADV treatment benefited with significant additional viral suppression and had a similar response to patients treated with TDF for 96 weeks.